Dr. James E. Callaway
Chief Executive Officer
Dr. Callaway has over three decades of biopharmaceutical development experience, primarily targeting CNS therapeutics and has served most recently as CEO for two privately-held biotech companies. Of importance to the KalGene mission, Dr. Callaway led the Elan Alzheimer’s Immunotherapy program that introduced the first disease-modifying biologics into clinical studies (AN1792, bapinuzumab, ACC001). In addition, as ArmaGen CEO he brought from the lab bench and into clinical studies the first biologics engineered to cross the blood-brain barrier in a manner similar to the FC5 construct licensed from the NRC.
Dr. Callaway has filed and defended numerous NDAs and INDs during his career, including shepherding the approval of MyoBloc® and the production of Tysabri®. He previously had senior development roles at Bayer Pharmaceuticals, SmithKline Beecham (GSK), and Ingene in Santa Monica, CA (Xoma) after receiving his Ph.D. in Biological Chemistry from UCLA with a focus on peptide chemistry.
Dr. T. Nathan Yoganathan
President and Chief Scientific Officer
Dr. T. Nathan Yoganathan is currently the President and Chief Scientific Officer of KalGene Pharmaceuticals. Dr. Yoganathan is a university and industrial research scientist, turned entrepreneur who became an experienced CEO, having successfully launched a public biotechnology company. He has over twenty-five years of experience in scientific research in cell signaling and gene expression technology, and has published several articles, and is an inventor of many patents.
Dr. Yoganathan is the recipient of numerous awards, including ones from the Natural Sciences and Engineering Research Council of Canada, and the Thyroid Foundation of Canada. He serves on a number of advisory boards for both government and industry, including the CIHR Strategic Training Program in the Bioinformatics Advisory Board, BIOTECanada’s Emerging Companies Advisory Board, and the Ontario Research Fund Advisory Board. He was elected as a Fellow of the Royal Society of Biology.
Dr. Yoganathan was a faculty member of the Department of Medicine at the University of Toronto, and was affiliated with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. He holds a B.Sc. (Honours) from the University of North London, a M.Sc. from the University of Sussex, and a Ph.D. from the University of Oslo.
Dr. John W. Gillard
Vice President Product Development
Dr. John Gillard, is KalGene's VP, Product Development. Dr. Gillard was a founder and Chief Scientific Officer (CSO) of Aegera Therapeutics Inc., which developed a pioneering oncology technology from discovery through to an out-licensed clinical product. He helped build the 55-person biotechnology company and attract more than $65M in investment over 12 years. He formerly worked at Merck and Biochem Pharma and has had extensive success managing academic-industry collaborative ventures, large pharma licensing deals and post-deal collaborations.
Dr. Michael Grundman
Dr. Grundman is President and CEO of Global R&D Partners, LLC, a consulting firm that works closely with pharmaceutical and biotechnology companies to develop novel agents for the diagnosis and treatment of serious and life threatening diseases.
Dr. Grundman is Professor of Neurosciences at the University of California San Diego (UCSD) and previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy Research & Development, LLC and as Vice President of Clinical Development at Elan Pharmaceuticals. Prior to joining industry, Dr. Grundman was Associate Director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD). He received his BA from New York University magna cum laude with Honors in Biochemistry. He obtained his MD and Neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University.
Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee and is an inventor on a number of patents related to Alzheimer’s disease therapy. Dr. Grundman has lectured at numerous national and international scientific meetings and has published over 90 clinical research articles. Dr. Grundman has over 25 years of experience in clinical research in CNS disorders. He led the clinical immunotherapy trials for Alzheimer’s Disease (AD) at Elan Pharmaceuticals including studies of monoclonal antibodies and active vaccines against beta amyloid. Dr. Grundman has worked since 2010 as consultant to a number of pharmaceutical companies, biotechnology companies and academia to advance treatments for CNS diseases.